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ABSTRACT
Introduction: Allergen bioavailability underpins the efficacy and safety of SLIT tablets. Three product-
related factors are likely to influence this: tablet potency, formulation and sublingual holding time.
Areas covered: Tablet formulation determines the rate and extent of solubilized allergen release. Using
validated in vitro dissolution assays, the two licensed grass pollen SLIT tablets are shown to release
≥85% of their total allergenic activity within several minutes. Sublingual holding time affects the
contact duration between solubilized allergens and sublingual tissue. Maximal uptake of allergens by
sublingual tissue requires ~5 minutes, with little uptake occurring within the first minute. A higher
potency tablet with longer sublingual holding time would provide higher bioavailability, while faster
rates of allergen release in vitro are unlikely to translate to a greater increase in bioavailability.
Differences in dissolution times cannot serve as a surrogate of in vivo bioavailability, and are not
related to differences in efficacy at the marketed tablet dosages. Rapid in vitro dissolution is likely not
a key requirement for inducing a potent immune response.
Expert opinion: In vitro dissolution cannot predict the clinical efficacy of SLIT tablets but could be
important in immune tolerance and safety. In addition, a discontinuous administration regimen may
have benefits for adherence and cost without compromising efficacy.
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Sublingual immunotherapy (SLIT) using natural allergen
extracts from grass or tree pollen, or house dust mite
(HDM), has become a mainstay of treatment for immuno-
globulin (Ig) E-dependent respiratory allergies. Two formula-
tions of grass-pollen SLIT tablets are currently licensed for
the treatment of allergic rhinitis (AR) in both Europe and
the USA [1]. The 5-grass pollen SLIT tablet (Oralair®;
Stallergenes Greer, Antony, France) contains purified, cali-
brated freeze-dried extract of pollen from sweet vernal
grass (Anthoxanthum odoratum), cocksfoot/orchard grass
(Dactylis glomerata), perennial rye grass (Lolium perenne),
meadow grass (Poa pratensis) and timothy grass (Phleum
pratense), and is used at a 300 index of reactivity (IR)
dose, equivalent to ~20–25 μg/mL of the group five major
allergens [1]. The compressed tablet contains allergen
extract plus mannitol, microcrystalline cellulose, croscarmel-
lose sodium, colloidal anhydrous silica, magnesium stearate
and lactose monohydrate [1]. The 1-grass pollen SLIT tablet
(Grazax®/Grastek®; ALK-Abelló, Hørsholm, Denmark) is
a 75,000 SQ-T (standardized quality tablet units) freeze-
dried SLIT tablet containing an allergen extract from
timothy grass (P. pratense), plus fish gelatin, mannitol and
sodium hydroxide [1].
SLIT tablets can be easily administered at home and do not
require injections [1]. The sublingual route is often used for the
administration of small molecule drugs (e.g. nitroglycerine or
opioid analgesics) to achieve fast absorption into the plasma. In
contrast, proteins of large molecular size do not cross the
mucosa to reach the bloodstream, but instead are captured
and processed by oral antigen-presenting cells (APCs) within
15–30 minutes [2], as assessed in vivo in animal models. APCs
loaded with allergen-derived peptides migrate to the cervical
lymph nodes within 12–24 h, where they interact with naive
CD4 + T cells to induce Th1 and regulatory T cells with suppres-
sive activity within 2–5 days. These CD4 + T cells subsequently
migrate into the blood and tissues, resulting in long-term aller-
gen-specific tolerance [3]. The sublingual route offers a special
advantage over other mucosal routes, because the antigen can
be captured and processed by APCs prior to any significant
proteolytic degradation occurring, thereby preserving the integ-
rity of T and B cell epitope repertoires [2].
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Allergen bioavailability (in this case, the availability to
uptake by APCs) underpins the efficacy and safety of SLIT
tablets, and at least two product-related factors, in addition
to tablet potency, are likely to influence this, namely tablet
formulation and sublingual holding time. Here, we examine
how the 5- and 1-grass pollen SLIT tablets differ with regards
to these factors and other key characteristics, and whether
differences between the products and formulations are of
clinical relevance.
2. Product and formulation characteristics of
licensed SLIT tablets for grass pollen-associated AR
The 1- and 5-grass pollen SLIT tablets have several differing
characteristics, as illustrated by Table 1.
2.1. Tablet potency and administration regimen
The clinical effectiveness of SLIT and wider allergen immu-
notherapy (AIT) is clearly dose-dependent [6], so clinicians
should be able to assess and compare the potency of the
various products available. Conversion to the bioequivalent
allergy unit (BAU), the only allergen unit approved and recog-
nized by a regulatory agency (the US Food and Drug
Administration), permits direct comparison of allergenic
potency in this way [7]. The optimal dose of the 5-grass pollen
tablet (300 IR) has been confirmed as 9,000 BAU, with higher
doses yielding no additional benefit [8,9]. This dose has
demonstrated long-term efficacy when prescribed in
a discontinuous, pre- and coseasonal regimen (starting
approximately 4 months prior to the pollen season) [10], and
the high potency of the 5-grass pollen tablet does not appear
to be associated with any safety signals or poor tolerabil-
ity [11].
The approved 75,000 SQ-T dose of the 1-grass pollen tablet
equates to 2,800 BAU; this dose is shown to be more effective
than the 2,500 and 25,000 SQ-T doses [12], and has also
demonstrated long-term efficacy when prescribed continu-
ously during the entire year [13]. In contrast to the clinical
development of the 5-grass pollen SLIT tablet, the optimal
dose of the 1-grass pollen SLIT tablet has not been confirmed
in dose-finding studies. Using the BAU, the 5-grass pollen SLIT
tablet appears to have >3-fold greater allergenicity than the
1-grass pollen SLIT tablet.
Economic and cost-effectiveness studies from Germany [14]
and Canada [15] have shown that the pre- and coseasonal
administration schedule of the 5-grass pollen SLIT tablet
appears to be associated with lower annual costs versus per-
ennial administration of the 1-grass pollen SLIT tablet, with
annual relative savings estimated at €1,142 and Canadian
$1,168, respectively [14,15]. Moreover, compliance with the
pre-/coseasonal regimen is high [16]. This has even been
demonstrated in a study that administered the 1-grass pollen
SLIT tablet to allergic patients according to a pre- and cosea-
sonal schedule instead of the recommended perennial sche-
dule [17]; in this study, compliance ranged from 72% in the
first year of treatment to 90% by the third year of treatment
[17]. The discontinuous administration regimen of the 5-grass
pollen SLIT tablet, in part because of its associated excellent
compliance, has therefore been proposed as inherently more
effective than perennial SLIT administration regimens [18].
2.2. Grass-pollen epitope coverage
Grass pollen has ubiquitous representation and significant
clinical importance worldwide [19]; the distribution of
Pooideae species varies across regions of Europe and North
America, meaning that pollen allergen exposure to specific
Article highlights
● Differences in AIT tablet dissolution times cannot be assumed as
a surrogate of in vivo bioavailability.
● Clinical efficacy of AIT tablets is unlikely related to a very rapid in vitro
allergen release at the marketed tablet dosages.
● The current knowledge of the oral immune response supports tablet
formulations with dissolution times superior to one minute.
● The relevant aspect for allergists is 6 versus 12 months of treatment
which is very important for long term compliance.
● Pre- and co-seasonal administration scheme of AIT tablets appears to
be associated with lower annual costs compared to perennial
administration.
Table 1. Product and formulation characteristics of the 5-grass pollen and 1-grass pollen SLIT tablets.
Characteristic 1-grass pollen SLIT tablet 5-grass pollen SLIT tablet








Tablet potency [7] 2,800 BAU 9,000 BAU
Dissolution time in vitro [27,28]
Physical disintegration of tablet





Clinical onset of action [40] Not determined 1 month
Grass pollen epitope coverage [20] + +++++
Efficacy in clinical trials [40] +++ +++
Safety in clinical trials [40] +++* +++
*Epinephrine was administered during clinical trials of the 1-grass pollen SLIT tablet [n = 1 adult receiving placebo, n = 1 adult receiving 1-grass pollen SLIT tablet
(both cases judged as treatment-related) and n = 2 pediatric subjects (of which 1 case was judged as treatment-related)] [40].
BAU, bioequivalent allergy unit; IR, index of reactivity; SLIT, sublingual immunotherapy; SQ-T, standardized quality tablet unit
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grasses differs between countries [20,21]. The pollen allergens
from different Pooideae species exhibit some shared T and
B cell epitopes, while group 1 and group 5 allergens display
species-restricted IgE epitopes [22]. The heterogeneity in grass
pollen epitopes across species can be differentiated by the
immune system, which may support the use of a mixed pollen
allergen extract over a single pollen allergen preparation [21].
The ability of the 5- and 1-grass pollen SLIT tablets to mimic
the range of epitopes that may be encountered in Europe has
been assessed by testing sera from adult patients living in
Spain (n = 19) or Sweden (n = 22) [20]. The 5-grass pollen
SLIT tablet demonstrated significantly greater inhibition of IgE
binding to pollen allergens from 12 grasses common to
Europe (bent grass, Bermuda grass, brome grass, cocksfoot,
false oat-grass, meadow fescue, meadowgrass, rye-grass,
sweet vernal-grass, timothy, wild oat and Yorkshire fog) than
did the 1-grass pollen SLIT tablet (p < 0.0001), both for the
total tested population and when stratified by country. This
difference between SLIT tablets was significantly greater for
Spanish than Swedish patients (p < 0.05). Fewer epitopes
associated with grass pollen allergy were present in the
1-grass pollen SLIT tablet, compared with the 5-grass pollen
SLIT tablet, and this difference was especially pronounced
when comparing sera from patients in the two geographical
regions [20]. In agreement with previous research [22], the
authors concluded that the 5-grass pollen SLIT tablet has
superior epitope coverage to the 1-grass pollen SLIT tablet,
especially for patients from Spain and other Southern
European countries, who may be less exposed to Timothy
grass than other grass species [20].
2.3. Tablet dissolution and allergen release
Absorption of small molecules through biological membranes,
including the transmucosal membrane, is positively related to
lipophilicity and negatively related to ionization and molecular
size. Transmucosal formulations of the small molecule, fentanyl,
achieve rapid dissolution and absorption across the mucosa
and are therefore more likely to match the time-course of
transitory flares of breakthrough pain than oral formulations
in patients with stable, controlled persistent pain [23].
Conversely, the superior immunogenicity of a novel intranasal
influenza vaccine, based on a novel polycationic lipid-ceramide
carbamoyl-spermine, is thought to be attributed to long reten-
tion of the vaccine at the administration site, eliciting strong
local and systemic immune responses [24]. Pharmacokinetic
and biodistribution studies following intranasal administration
of the vaccine in mice showed that both the lipids and antigens
were retained in the nose and lung for at least 24 h, and this
retention appeared to be correlated with enhanced immuno-
genicity [24]. Therefore, rapid dissolution is not necessarily a key
factor for induction of a potent immune response to medica-
tions administered via the nasal route. This might also apply to
oral administered agents.
SLIT relies on the efficient delivery of soluble allergens to the
sublingual mucosa, in a form that is appropriate for capture by
the immunocompetent cells that reside there. After entering
the oral mucosa, allergens are taken up by resident APCs, which
subsequently migrate to the draining cervical lymph nodes;
here, they elicit allergen specific Th1/Treg responses, thus sup-
pressing the established allergic Th2 response, and leading to
the gradual development of immune tolerance [3,25]. As men-
tioned previously, allergen bioavailability within the sublingual
mucosa is the foundation of both the safety and efficacy of AIT
products. The European Medicines Agency defines bioavailabil-
ity as ‘the rate and extent to which the active substance or
active moiety is absorbed from a pharmaceutical form and
becomes available at the site of action’ [26]. Therefore, any
rigorous assessment of allergen bioavailability from SLIT tablets
should consider several parameters, including allergen content
and release kinetics after tablet dissolution, the effect of salivary
components on allergen degradation, and the extent of aller-
gen uptake by epithelial cells and APCs in the sublingual
mucosa [27].
Depending on the method used, in vitro dissolution
assays of SLIT tablets can produce dramatically different
results. Using a method advocated by the Japanese
Pharmacopoeia, the 1-grass pollen SLIT tablet was shown
to dissolve completely within 1 s versus incomplete dissolu-
tion of the 5-grass pollen SLIT tablet after 30 s, and this
difference between dissolution times was significant
(p < 0.001) [28]. Grass group 5 major allergen content was
measured by enzyme-linked immunosorbent assay using
a proprietary monoclonal antibody against Phl p 5, after
dissolution of either grass pollen SLIT tablet in
a phosphate buffer approximating human saliva in pH,
ionic strength and total protein content (but not containing
salivary enzymes or any other components of saliva). Full
recovery of the 1-grass pollen SLIT tablet allergen content
was achieved after ~15 s, whereas only ~16% of Phl p 5
content was released from the 5-grass pollen SLIT tablet
after 120 s (p < 0.0001 for comparison of released Phl p 5)
[28]. It should be remembered that quantification of Phl p 5
can be affected by the specificity and sensitivity of the
antibodies used for detection, and/or whether they are
mono- or polyclonal antibodies; moreover, quantification of
Phl p 1/grass group 1 major allergens has not been assessed
for either SLIT tablet formulation.
Comparable assays to those used for grass pollen have
been used to evaluate SLIT tablets containing house dust
mite (HDM) allergens (12 SQ HDM or 300 IR HDM).
Disintegration times were ~1 s versus 45 s for the 12 SQ
HDM and 300 IR HDM SLIT tablets, respectively (p < 0.0001).
Complete release of Der f 1, Der p 1 and Der 2 from the 12 SQ-
HDM SLIT tablet was obtained within 30 s, whereas for the 300
IR HDM SLIT tablet, soluble HDM major allergen content con-
tinued to increase over time, but did not reach complete
release, even after 10 minutes [29,30]. In contrast, using an
in vitro dissolution assay endorsed by the European
Pharmacopoeia (Ph. Eur. 2.9.3 dissolution test for solid dosage
forms, apparatus 4 flow-through cell [31]), ≥85% of total aller-
genic activity is shown to be released from 300 IR and 100 IR
HDM and 5 grass SLIT tablets within 2 minutes (Figure 1) [27].
Rapid complete release of grass pollen or HDM major
allergens (e.g. within seconds) may contribute to a faster aller-
gen saturation of APCs and prevent optimal allergen targeting
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Figure 1. Kinetics of allergen activity release and dissolution of 300 IR and 100 IR HDM and 5 grass SLIT tablets in vitro.
An in vitro dissolution assay endorsed by the European Pharmacopoeia (Ph. Eur. 2.9.3 dissolution test for solid dosage forms, apparatus 4 flow-through cell [31]) was used to investigate the
dissolution time of 6 replicate samples of the 300 IR or 100 IR HDM and 5 grass pollen SLIT tablets, and the amount of allergenic activity released at each time point was measured using an
ELISA-based assayELISA, enzyme-linked immunosorbent assay; HDM, house dust mite; IR, index of reactivity; SLIT, sublingual immunotherapy.
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[27]. The kinetics of allergen uptake by APCs in the sublingual
mucosa are dose-dependent up to the point of saturation, and
therefore are an important contributor to allergen bioavail-
ability [32]. The 5-grass pollen and 300 IR HDM SLIT
tablets have been designed to sustain allergen release over
2–3 minutes, with the aim of promoting allergen uptake by
APCs without triggering rapid activation of local pro-
inflammatory mast cells [33]. It is unclear whether the rapid
release of allergen from the 1-grass pollen SLIT tablet offers an
advantage over the more gradual release from the 5-grass
pollen SLIT tablet, because the production of high local con-
centrations of proteins may overwhelm immune cell uptake
mechanisms. Unlike small molecule therapeutics (e.g. fentanyl,
nitroglycerin), allergen uptake into sublingual tissue is com-
paratively slow and can be saturated, because it involves the
transport of bulky proteins across cellular barriers.
Proteins that are swallowed are rapidly degraded by
digestive enzymes and absorbed [34,35], and this process
may alter the T and B cell epitope repertoire from that
seen with oromucosal or nasal uptake. In a study that
investigated the in vivo distribution kinetics of radiola-
belled Parietaria judaica allergen after sublingual, oral
and intranasal administration in healthy, non-allergic
humans, no degradation of the labelled allergen occurred
in the sublingual space for up to 20 minutes after sub-
lingual administration, and there was no absorption of the
radiolabelled allergen through the sublingual mucosa into
the bloodstream for up to 30 minutes, but swallowed
labelled allergen underwent rapid hydrolysis and absorp-
tion in the gastrointestinal tract [34]. These findings are
consistent with the large size and relatively high molecu-
lar weight of the protein, which also possesses
a hydrophilic surface [34]. Studies in allergic subjects
using the radiolabeled allergens, Par j 1 and Der p2,
administered sublingually have demonstrated that sensiti-
zation to the allergen affects at some extent its biodistri-
bution and kinetics, especially at mucosal level [35,36].
The sublingual holding (swallowing) time affects the
time of contact between solubilized allergens and sublin-
gual tissue, because swallowing will remove the majority
of unabsorbed allergens from the sublingual space, pre-
venting further uptake. It takes 5 minutes for maximal
uptake of allergens by the sublingual tissue, with little
uptake within the first minute [32] (Figure 2). In light of
this, the sublingual holding time should be at least several
minutes. Early swallowing (e.g. at 1 minute) may reduce
the uptake of allergens.
Human saliva contains >3,000 distinct proteins, includ-
ing enzymes, hormones, antibodies and cytokines [37], any
of which may promote allergen degradation, decrease
allergen potency, and preclude optimal targeting onto
epithelial cells and APCs. Such effects are difficult, if not
impossible, to model and assess using in vitro dissolution
assays. For these reasons, although differences in dissolu-
tion times can be demonstrated using in vitro dissolution
assays, these cannot serve as a surrogate of bioavailability,
because they lack any direct correlation with an in vivo
sustained effect [27].
3. Clinical efficacy and safety of the 1- and 5-grass
pollen SLIT tablets
The optimal allergen dose for SLIT should achieve the highest
therapeutic effect without compromising safety or leading to
unacceptable allergen-mediated discomfort during treatment
[29]. Both the 1- and 5-grass pollen SLIT tablets have been
extensively studied during clinical development, and their favor-
able efficacy and safety profiles are well established (Table 1).
Perennial treatment with the 1-grass pollen SLIT tablet leads to
clinical improvement in adults suffering from rhinoconjunctivitis
that is sustained over the long term [13,38]. The 5-grass pollen
SLIT tablet, administered in a pre-coseasonal schedule, is effec-
tive in reducing allergic symptoms and symptomatic medication
use, and improving a patient’s quality of life [1,39]. Improvement
in symptoms upon allergen exposure is detectable after 1 month
of treatment with the 5-grass pollen SLIT tablet [40], demonstrat-
ing that although it may have a slower in vitro dissolution time
than the 1-grass pollen SLIT tablet, allergen release is sufficient to
achieve clinical efficacy within only 1 month. The clinical onset of
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Figure 2. Kinetics of grass pollen allergen binding by oromucosal Langerhans cells ex vivo.
This was an ex vivo study not related to SLIT tablet use. Using oromucosal tissue from individuals with grass pollen allergy (n = 5) or non-atopic individuals (n = 5), incubated with
fluorescein isothiocyanate-coupled Phl p 5 (1 mg/mL) at 37°C for the specified times, significant binding of Phl p 5 to Langerhans cells was detected from 5°minutes of allergen exposure
onwards, and binding capacity was comparable between tissue samples. Figure adapted from Allam et al. 2010 [32].SLIT, sublingual immunotherapy.
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The safety profiles of both SLIT tablet products in clinical
trials are similar, with the majority of adverse events being local,
mild-to-moderate reactions that resolve without sequelae in the
first 1–2 weeks of treatment. Neither SLIT tablet products
caused anaphylactic shock or fatalities in clinical trials, although
some grade 1–3 systemic AEs were observed. Notably, while no
use of epinephrine was documented in trials of the 5-grass
pollen SLIT tablet, 4 cases of epinephrine autoinjector use
occurred during clinical trials of the 1-grass pollen SLIT tablet
conducted either with adult or pediatric patients [40–42].
4. Conclusion
The optimal dose of the 5-grass pollen tablet (300 IR; 9000
BAU) has demonstrated long-term efficacy when prescribed in
a discontinuous, pre- and coseasonal regimen. Importantly,
the high potency of the 5-grass pollen tablet does not appear
to be associated with any safety signals or poor tolerability.
The optimal dose of the 1-grass pollen SLIT tablet has not
been confirmed, but the approved dose (75,000 SQ-T; 2800
BAU) has demonstrated long-term efficacy when prescribed
continuously during the entire year. The pre-/coseasonal regi-
men of the 5-grass pollen SLIT tablet appears to be associated
with excellent adherence, and lower annual costs versus the
1-grass pollen SLIT tablet.
Differences between the licensed 1- and 5-grass pollen SLIT
products are evident. A recent report has implied that in vitro
dissolution kinetics of SLIT tablets correlate with bioavailability
and clinical efficacy [28]; however, it is clear that this is not the
case, and in vitro dissolution rate cannot be used as a reliable
indicator of clinical efficacy. Based on the current knowledge of
the oral immune response, a formulation encompassing a very
rapid dissolution may not be optimal for sublingual administra-
tion of allergens. A direct head-to-head comparison between the
two grass pollen SLIT tablet products, to assess any differences in
the extent of their efficacy, has yet to be performed.
5. Expert opinion
The biovailability of sublingual AIT in tablets is certainly of
central importance, and likely related also to efficacy. It is true
that the unique mode of action of SLIT (modulation of the
immune response) and the complexity of events following
sublingual administration make it difficult to study in detail
all of the aspects involved. Nonetheless, immunological stu-
dies on allergen uptake by APCs in relation to the dissolution
of tablets would allow us to further improve the efficacy of
SLIT.
It is clear that the primary endpoint to be evaluated when
comparing different SLIT formulations should be clinical effi-
cacy supported by analysis of systemic biomarkers (for exam-
ple, IgG4 or IgE), but this will require expensive and complex
head-to-head trials, and this is not immediately feasible.
As already discussed, it is impossible to draw conclusions
on the bioavailability and clinical efficacy of SLIT tablets, based
on their in vitro dissolution time. However, the different dis-
solution times between the grass pollen SLIT tablet products
could potentially influence administration.
Further investigation of the relationship between allergen
retention at the administration site, and the elicited local and
systemic immune responses, as well as the optimal frequency
and duration of administration to gain an appropriate and sus-
tained immune response is needed. Additionally, a better under-
standing of the possible differences in, and magnitude and
extent of, humoral and mucosal immune responses provided
by monovalent or multivalent formulations may pave the way
for improving and optimizing the efficacy of future SLIT. One can
speculate that tablets designed to sustained allergen release
over 2–3 minutes, without triggering rapid activation of local
proinflammatory mast cells, are behind good safety profile.
Real-life data collected from registries of patients using SLIT
and other treatments for grass pollen allergy are starting to
provide more insights about the long-term effects of SLIT, and
in the near future, will likely play a greater role in guiding treat-
ment, especially regarding the most appropriate and effective
administration regimen. Pre- and coseasonal administration
appears to have advantages over perennial administration in
terms of a reduced frequency and duration of administration,
and the benefits for adherence and cost savings arising from this.
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